Triesence is a drug owned by Harrow Eye Llc. It is protected by 3 US drug patents filed in 2013. Out of these, 2 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 17, 2029. Details of Triesence's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6395294 | Method of visualization of the vitreous during vitrectomy |
Jan, 2020
(4 years ago) |
Expired
|
| US8211880 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Mar, 2029
(4 years from now) | Active |
| US8128960 | Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection |
Dec, 2029
(5 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Triesence's patents.
Latest Legal Activities on Triesence's Patents
Given below is the list of recent legal activities going on the following patents of Triesence.
| Event | Date | Patent/Publication |
|---|---|---|
 | ||
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 16 Oct, 2023 | US8211880 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 16 Oct, 2023 | US8211880 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 15 Mar, 2023 | US8128960 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 15 Mar, 2023 | US8128960 |
| Change in Power of Attorney (May Include Associate POA) | 07 Mar, 2023 | US8128960 |
| Email Notification | 07 Mar, 2023 | US8128960 |
| Email Notification | 07 Mar, 2023 | US8211880 |
| Change in Power of Attorney (May Include Associate POA) | 07 Mar, 2023 | US8211880 |
| Correspondence Address Change | 01 Mar, 2023 | US8211880 |
| Correspondence Address Change | 01 Mar, 2023 | US8128960 |
US patents provide insights into the exclusivity only within the United States, but Triesence is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Triesence's family patents as well as insights into ongoing legal events on those patents.
Triesence's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Triesence's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 17, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Triesence Generics:
Triamcinolone Acetonide is the generic name for the brand Triesence. 47 different companies have already filed for the generic of Triesence, with Astellas having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Triesence's generic
About Triesence
Triesence is a drug owned by Harrow Eye Llc. It is used for visualization and treatment of ophthalmic disorders during vitrectomy surgery. Triesence uses Triamcinolone Acetonide as an active ingredient. Triesence was launched by Harrow Eye in 2007.
Market Authorisation Date:
Triesence was approved by FDA for market use on 29 November, 2007.
Active Ingredient:
Triesence uses Triamcinolone Acetonide as the active ingredient. Check out other Drugs and Companies using Triamcinolone Acetonide ingredient
Treatment:
Triesence is used for visualization and treatment of ophthalmic disorders during vitrectomy surgery.
Dosage:
Triesence is available in injectable form for intravitreal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 40MG/ML (40MG/ML) | INJECTABLE | Prescription | INTRAVITREAL |